Table 1.
Metabolites Quantified by the LCECA platform.
Figure 1.
Changes in metabolites within (A) tryptophan, (B) tyrosine and (C) purine metabolism pathways.
Abbreviations: HIOMT = hydroxyindole-O-methyltransferase; 5-HIAD = 5-Hydroxyindole acetyldehyde; NM-5-HT = N-methyl serotonin; 5-HTPOL = 5-Hydroxytryptophol; 5-MIAA = 5-Methoxyindole acetic acid; 5-MTPM = 5-methoxytryptamine. For the remaining metabolites, see Table 1.
Table 2.
Metabolic changes after one week treatment with sertraline and placebo.
Table 3.
Metabolic changes after four week treatment with sertraline and placebo.
Figure 2.
Metabolites within methoxyindole branch of tryptophan pathway correlated with treatment response.
Panels A and B show correlations of metabolites at baseline with the four week treatment response in the sertraline and placebo groups, respectively. The correlations are color coded as indicated by the color bar. Panels C and D show four week metabolic changes unique to responders in the sertraline and placebo groups respectively. Abbreviations: HIOMT = hydroxyindole-O-methyltransferase; 5-HIAD = 5-Hydroxyindole acetyldehyde; NM-5-HT = N-methyl serotonin; 5-HTPOL = 5-Hydroxytryptophol; 5-MIAA = 5-Methoxyindole acetic acid; 5-MTPM = 5-methoxytryptamine. For the remaining metabolites, see Table 1.
Table 4.
Correlations of pre-treatment levels of metabolites within the tryptophan pathway to four-week percent change in HAMD17 scores in Sertraline group.
Table 5.
Correlations of pre-treatment levels of ratios of metabolites within the tryptophan pathway to four week percent change in HAMD17 scores in Sertraline group.
Table 6.
Change in tryptophan pathway ratios in responders and nonresponders to sertraline.
Table 7.
Correlations of pre-treatment levels of metabolites within the tryptophan pathway to four-week percent change in HAMD17 scores in Placebo group.
Table 8.
Correlations of pre-treatment levels of ratios of metabolites within the tryptophan pathway to four week percent change in HAMD17 scores in Placebo group.
Table 9.
Change in tryptophan pathway ratios in responders and nonresponders to placebo.